Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIP floxuridine plus systemic chemotherapy for potentially resectable colorectal liver metastases
NL-OMON55263Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of floxuridine, fluorouracil, folinic acid, oxaliplatin and irinotecan in colorectal adenocarcinoma and colorectal cancer liver metastasis (CRLM), sponsored by Netherlands Cancer Institute. Started Sep 2020; status: active, not recruiting.
02
Drugs
floxuridinefluorouracilfolinic acidoxaliplatinirinotecan
03
Conditions
colorectal adenocarcinomacolorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on NL-OMON55263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55263.